Result:Very Good· Market: Flat#Margin expansion#Broad based
| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 158.71 | 14.0% | 32.0% |
| Total Income | 159.91 | 9.1% | 30.7% |
| Expenditure | 138.31 | 13.3% | 26.5% |
| PBT | 21.60 | 11.8% | 66.6% |
| Net Profit | 16.25 | 11.7% | 68.8% |
| OPM | 17.68% | 0.95pp | 3.41pp |
| NPM | 10.16% | 2.39pp | 2.29pp |
| EPS | 26.30 | 11.7% | 68.8% |
Core-driven 32% revenue growth with OPM expanding ~340bps (14.3%→17.7%) drove 69% PAT growth despite lower other income, a standout for a small-cap pharma/specialty chemicals name.
Informational and educational content only. Not investment advice.